Jazz Pharmaceuticals plc (JAZZ) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $0.00; Additional Paid in Capital, Common StockUSD $4.33B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-662.50M; Retained Earnings (Accumulated Deficit)USD $1.13B.
- 2026-03-31: Common Stock, Value, IssuedUSD $0.00; Additional Paid in Capital, Common StockUSD $4.24B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-651.00M; Retained Earnings (Accumulated Deficit)USD $939.20M.
- 2025-12-31: Common Stock, Value, IssuedUSD $0.00; Additional Paid in Capital, Common StockUSD $4.24B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-568.60M; Retained Earnings (Accumulated Deficit)USD $646.10M.
- 2025-09-30: Common Stock, Value, IssuedUSD $6.00K; Additional Paid in Capital, Common StockUSD $4.09B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-569.90M; Retained Earnings (Accumulated Deficit)USD $442.73M.
Jazz Pharmaceuticals plc Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Preferred Stock, Value, Issued USD | AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature USD | Adjustments to Additional Paid in Capital, Other USD | Noncontrolling Interest, Increase from Business Combination USD | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation USD | Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $4.33B | $-662.50M | $1.13B | $4.80B | 3 month · $74.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $4.24B | $-651.00M | $939.20M | $4.53B | 3 month · $73.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $4.24B | $-568.60M | $646.10M | $4.32B | 12 month · $294.29M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $6.00K | $4.09B | $-569.90M | $442.73M | $3.96B | 3 month · $88.47M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $6.00K | $4.00B | $-485.77M | $191.31M | $3.71B | 3 month · $66.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $6.00K | $3.93B | $-785.61M | $1.03B | $4.17B | 3 month · $67.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $6.00K | $3.91B | $-947.67M | $1.13B | $4.09B | 12 month · $250.69M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $6.00K | $3.84B | $-603.40M | $936.23M | $4.17B | 3 month · $60.17M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $6.00K | $3.78B | $-888.23M | $871.18M | $3.76B | 3 month · $56.74M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $6.00K | $3.71B | $-882.39M | $864.04M | $3.70B | 3 month · $63.13M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $6.00K | $3.70B | $-842.15M | $878.66M | $3.74B | 12 month · $227.32M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $6.00K | $3.64B | $-1.04B | $884.30M | $3.49B | 3 month · $56.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $6.00K | $3.58B | $-866.82M | $811.85M | $3.53B | 3 month · $61.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $6.00K | $3.51B | $-980.23M | $803.01M | $3.34B | 3 month · $56.65M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $6.00K | $3.48B | $-1.13B | $733.59M | $3.09B | 12 month · $223.28M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $6.00K | $3.39B | $-1.62B | $974.31M | $2.75B | 3 month · $56.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $6.00K | $3.31B | $-1.11B | $993.96M | $3.20B | 3 month · $54.41M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $6.00K | $3.24B | $-590.72M | $959.35M | $3.61B | 3 month · $50.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $6.00K | $3.53B | $-400.36M | $830.23M | $3.97B | 12 month · $189.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $6.00K | $3.47B | $-397.52M | $865.58M | $3.94B | 3 month · $54.01M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $6.00K | $3.40B | $-190.94M | $918.41M | $4.13B | 3 month · $48.12M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $6.00K | $2.69B | $-179.43M | $1.28B | $3.80B | 3 month · $34.56M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $6.00K | $2.63B | $-134.35M | $1.16B | $3.66B | 12 month · $121.09M | (m) | (m) | (m) | (m) | (m) | 12 month · $176.26M | (m) | (m) | (m) | (m) |
| 2020-09-30 | $6.00K | $2.54B | $-187.80M | $1.03B | $3.38B | 3 month · $30.31M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $6.00K | $2.50B | $-236.11M | $878.25M | $3.14B | 3 month · $30.60M | (m) | (m) | (m) | 3 month · $176.26M | (m) | 3 month · $176.26M | (m) | (m) | (m) | (m) |
| 2020-03-31 | $6.00K | $2.29B | $-257.44M | $770.93M | $2.81B | 3 month · $28.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $6.00K | $2.27B | $-223.39M | $1.07B | $3.11B | 12 month · $111.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $6.00K | $2.21B | $-259.44M | $1.10B | $3.05B | 3 month · $28.82M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $6.00K | $2.17B | $-210.44M | $1.02B | $2.98B | 3 month · $28.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $6.00K | $2.13B | $-220.67M | $819.85M | $2.73B | 3 month · $27.86M | (m) | (m) | $2.73B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-01-01 | (m) | (m) | (m) | $845.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $6.00K | $2.11B | $-197.79M | $841.05M | $2.76B | 12 month · $102.73M | (m) | (m) | $2.76B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $6.00K | $2.08B | $-179.47M | $1.13B | $3.03B | 3 month · $25.11M 9 month · $75.68M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $6.00K | $2.04B | $-168.23M | $1.00B | $2.87B | 3 month · $26.29M 6 month · $50.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $6.00K | $1.96B | $-98.77M | $929.05M | $2.79B | 3 month · $24.28M | (m) | (m) | $2.79B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-01-01 | (m) | (m) | $-140.82M | $917.62M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $6.00K | $1.94B | $-140.88M | $917.96M | $2.71B | 12 month · $107.25M | (m) | (m) | $2.71B | 12 month · $149.77M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $6.00K | $1.90B | $-158.99M | $728.12M | $2.47B | 9 month · $79.75M | (m) | (m) | (m) | 9 month · $149.77M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $6.00K | $1.72B | $-210.25M | $690.16M | $2.20B | 6 month · $52.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $6.00K | $1.68B | $-299.84M | $601.52M | $1.98B | 3 month · $25.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $6.00K | $1.67B | $-317.33M | $528.91M | $1.88B | 12 month · $99.39M | (m) | (m) | $1.88B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $6.00K | $1.64B | $-235.38M | $315.42M | $1.83B | 9 month · $75.18M | (m) | (m) | $1.72B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $6.00K | $1.62B | $-249.99M | $324.84M | $1.80B | 6 month · $50.33M | (m) | (m) | $1.69B | (m) | (m) | (m) | (m) | (m) | 6 month · $3.50M | 6 month · $14.28M |
| 2016-03-31 | $6.00K | $1.59B | $-222.28M | $242.44M | $1.71B | 3 month · $24.61M | (m) | (m) | $1.61B | (m) | (m) | (m) | (m) | (m) | 3 month · $7.94M | 3 month · $12.48M |
| 2015-12-31 | $6.00K | $1.56B | $-267.47M | $302.69M | $1.71B | 12 month · $91.80M | (m) | (m) | $1.60B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $6.00K | $1.53B | $-231.28M | $260.18M | $1.56B | 9 month · $67.73M | (m) | (m) | $1.56B | (m) | (m) | (m) | (m) | (m) | 9 month · $-320.00K | 9 month · $320.00K |
| 2015-06-30 | $6.00K | $1.51B | $-248.04M | $181.83M | $1.45B | 6 month · $44.39M | (m) | (m) | $1.45B | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · $16.68M |
| 2015-03-31 | $6.00K | $1.49B | $-278.58M | $95.07M | $1.31B | 3 month · $20.90M | (m) | (m) | $1.31B | (m) | (m) | (m) | (m) | (m) | 3 month · $10.63M | 3 month · $14.78M |
| 2014-12-31 | $6.00K | $1.46B | $-122.10M | $34.70M | $1.37B | 12 month · $70.06M | (m) | (m) | $1.37B | 12 month · $126.86M | (m) | (m) | (m) | 12 month · $136.58M | (m) | (m) |
| 2014-09-30 | $6.00K | $1.43B | $-57.13M | $-34.67M | $1.34B | 9 month · $50.92M | (m) | (m) | $1.34B | 9 month · $126.86M | (m) | (m) | (m) | 9 month · $136.58M | 9 month · $4.08M | 9 month · $17.31M |
| 2014-06-30 | $6.00K | $1.27B | $59.95M | $-53.95M | $1.28B | 6 month · $32.48M | (m) | (m) | $1.28B | (m) | (m) | (m) | (m) | 6 month · $136.58M | 6 month · $792.00K | 6 month · $10.55M |
| 2014-03-31 | $6.00K | $1.25B | $70.89M | $-74.12M | $1.25B | 3 month · $14.31M | (m) | (m) | $1.27B | (m) | (m) | (m) | (m) | 3 month · $136.58M | 3 month · $5.78M | 3 month · $9.36M |
| 2013-12-31 | $6.00K | $1.22B | $56.15M | $18.53M | $1.30B | 12 month · $44.37M | (m) | (m) | $1.30B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $6.00K | $1.20B | $44.62M | $-2.67M | $1.24B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $6.00K | $1.18B | $19.22M | $-29.26M | $1.18B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $6.00K | $1.17B | $10.61M | $-17.87M | $1.16B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $6.00K | $1.15B | $31.05M | $-61.30M | $1.12B | 12 month · $23.13M | $0.00 | (m) | $1.12B | (m) | 12 month · $241.00K | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | $6.00K | $1.13B | $13.86M | $-261.85M | $886.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $6.00K | $1.13B | $-388.00K | $-295.06M | $831.46M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $6.00K | $1.10B | (m) | $-322.20M | $781.83M | (m) | (m) | $3.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-01-18 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $575.90M | (m) | (m) | (m) |
| 2011-12-31 | $4.00K | $542.70M | $-31.00K | $-349.88M | $192.79M | 12 month · $20.50M | $0.00 | $-31.00K | $192.79M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | $4.00K | $528.68M | (m) | $-387.36M | $141.33M | (m) | (m) | $-2.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $4.00K | $521.43M | (m) | $-419.84M | $101.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $4.00K | $505.41M | (m) | $-474.87M | $30.55M | 12 month · $8.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | $-72.83M | 12 month · $5.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | $-92.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |